All News
Psoriatic Arthritis: Hit hard and Early
d
EurekAlert!
Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not select for poor prognosis.
Read Article
In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA.
Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years.
Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
There is still hope for vagal nerve stimulation in RA!
RCT RESET-RA 240+pts multibioIR
Implantable cervical device
Meets Primary endpoint ACR 20 wk12
Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham
EULAR Good response 61% vs 42% sham Wk 12
SAE rate 1.7%
#OP0190 #EULAR2025 https://t.co/DCON01XXgd
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals.
@RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF
Mrinalini Dey DrMiniDey ( View Tweet)
Difficult-to-treat & early PsA at #EULAR2025
GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus.
Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
Dr. John Cush RheumNow ( View Tweet)
▶️Erosive hand OA
🔺Gull-wing erosion @ DIPJs ✅
🔺Saw-tooth erosions @ PIPJs ✅
#OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down.
If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate.
We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP
David Liew drdavidliew ( View Tweet)
In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising.
@RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6
Mrinalini Dey DrMiniDey ( View Tweet)
Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA.
-Smoking and psoriasis were characteristics associated with D2M disease.
-In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Sex differences in biologic response in PsA.
DISCOVER-2 post hoc analysis showed:
•Radiographic progression at Week
♂️: 2.22 units
♀️: 1.10 units
•Early ACR-like response (cDAPSA LDA at 8wks) linked to less damage in men (0.39 vs 2.24)
Women less likely to progress https://t.co/NhBkXbuLjO
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 Abstr#OP0006. There is no standardised definition for complete renal response in #lupus nephritis. Post-hoc analysis of REGENCY showed Obinutuzumab + SOC was superior to PBO + SOC if endpoints for voclosporin and belimumab RCTs were used. Effect size ~13-16% @RheumNow https://t.co/q8MNAV8XF3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Dr. John Cush RheumNow ( View Tweet)
T2T in #gout w serum #uric #acid / #urate target
SAVES LIVES
Study of achievement of target 🎯
⬇️CVE and death
If not achieving Urate <360
T2T also reduced baseline #SUA
#EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU
Janet Pope Janetbirdope ( View Tweet)
#Oninutuzumab works in
#lupus #nephritis #LN
no matter how you vary the
#renal #responses
Of various definitions of
#Complete & #Partial #renal #responses
abst#OP0006
#EULAR25 @eular_org @RheumNow
Not surprised 😲 https://t.co/Zn2lXkddez
Links:
Janet Pope Janetbirdope ( View Tweet)
1 shot will do!
#symptomatic #Knee #OA given #gene #therapy #intra-#articular
Seemed to last up to 104 weeks!
But no placebo
small safety study but sustained #WOMAC responses
Needs large #RCT but v interesting
#EULAR2025 @RheumNow @eular_org
Abst# POS0492 https://t.co/hqTqBorrbA
Links:
Janet Pope Janetbirdope ( View Tweet)
Exciting results from ARGO trial:
-Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA.
-Met primary endpoint of ACR50 at week 12 vs PBO.
-62% achieved MDA
-48% achieved composite of ACR 70+PASI 100
Looking forward to phase 3 results!!!
Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort
-Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated.
-In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5
Adela Castro AdelaCastro222 ( View Tweet)
So much needed in SLE and pregnancy
1. Risk stratification at diagnosis
2. Pregnancy counseling at dx and >1 y before pregnancy
3. Close collab with GYN necessary
4. Challenging management given gaps in evidence.
#EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452
Links:
Adela Castro AdelaCastro222 ( View Tweet)
